do peptides FAQ

This occurs because growth hormone stimulates sodium retention and increases intracellular glycogen storage. Each gram of glycogen binds 3–4g of water. The effect is temporary and typically resolves within 2–3 weeks as the body adjusts to elevated GH levels. If retention persists or interferes with study outcomes, reduce peptide dose by 25–30% or switch from GHRP-6 (which has stronger ghrelin effects and appetite stimulation) to ipamorelin, which produces less aldosterone-mediated fluid retention. Diuretic use is not recommended as it can confound lean mass measurements and disrupt electrolyte balance critical for protein synthesis.

Never double-dose. If you miss a weekly injection by fewer than 5 days, administer the missed dose as soon as you remember and resume your regular schedule. If more than 5 days have passed, skip the missed dose entirely and inject on your next scheduled date. Doubling doses spikes plasma concentration beyond the therapeutic window, dramatically increasing GI side effects without proportional benefit. Missing one dose during maintenance phase rarely affects appetite suppression due to the 5–7 day half-life of most GLP-1 agonists. The previous dose is still partially active.

Lyophilized (freeze-dried) peptides are stable at room temperature for weeks, but once reconstituted with bacteriostatic water, they must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. The peptide loses its three-dimensional structure, which means it loses its biological activity. A denatured peptide won't harm you, but it won't work either. Always verify storage conditions when sourcing research peptides.

Start with BPC-157 if the primary problem is tendon or ligament laxity. It excels at connective tissue repair through angiogenesis. Use TB-500 if the issue is osteoarthritic cartilage degradation with inflammatory flare-ups. Its cytokine modulation addresses the catabolic cascade driving joint space narrowing. You can stack both, but begin with one to isolate response. Typical protocols run 4–8 weeks before reassessment.

Reassess dosing accuracy, peptide purity, and storage conditions before concluding peptides don't work. Temperature excursions above 8°C during storage denature BPC-157 irreversibly. If your vial wasn't refrigerated continuously, the peptide is inactive regardless of dose. Verify you're using research-grade compounds with third-party purity testing; underdosed or contaminated peptides from unverified sources explain most

Start a structured peptide protocol under supervision if pain persists beyond 12 weeks despite conservative treatment. BPC-157 at 500mcg daily via subcutaneous injection for 10 weeks addresses structural cartilage damage that physical therapy and NSAIDs can't. PT strengthens surrounding muscles but doesn't regenerate worn cartilage, and NSAIDs only block pain signaling. Combine peptides with continued PT for compounding benefits: peptides repair tissue while PT restores mechanical function.

Treatment-resistant depression (defined as failure to respond to two or more antidepressant trials) affects roughly 30% of patients with major depressive disorder. If traditional monoamine-based treatments haven't worked, targeting neuroplasticity pathways makes mechanistic sense. That's the rationale behind ketamine and esketamine (Spravato), both of which promote BDNF signaling and synaptic remodeling. Peptides like Cerebrolysin operate through similar pathways but without the FDA oversight or standardized dosing protocols that ketamine clinics provide. The risk: you're taking a compound whose psychiatric dosing hasn't been validated in controlled trials, often sourced from suppliers whose product purity and potency aren't independently verified. If you're considering this route, work with a prescriber familiar with off-label peptide use and willing to monitor psychiatric response longitudinally.

Consult your prescribing physician before combining thymic peptides with immunosuppressants like methotrexate, azathioprine, or biologics. Thymalin restores immune regulatory function, which could theoretically counteract the immunosuppressive mechanism of drugs designed to reduce overall immune activity. The interaction hasn't been studied in controlled trials. Most clinical peptide research excluded patients on concurrent immunosuppression to isolate peptide effects.

No known pharmacokinetic interactions exist between amphetamines or methylphenidate and neuropeptides like Cerebrolysin or Dihexa, but that's based on absence of evidence, not evidence of absence. Stimulants increase dopamine acutely; peptides like P21 or Dihexa work on synaptic structure over weeks. The mechanisms are complementary, not competitive. The risk isn't drug interaction. It's polypharmacy without medical oversight. If you're adding peptides to a stimulant regimen, do it under a prescriber who can monitor for adverse effects and adjust dosing.

BPC-157 was originally studied as a gastric protective compound and counteracts NSAID-induced mucosal damage. A 2020 study in the World Journal of Gastroenterology found BPC-157 accelerated healing of ibuprofen-induced gastric ulcers in rats by 78% compared to controls. If you're managing joint pain with daily NSAIDs and developing upper GI symptoms, BPC-157 may address both the joint pathology and the drug side effects simultaneously.

This signals receptor desensitisation. The pituitary's ghrelin receptors downregulate in response to sustained supraphysiological stimulation, reducing GH pulse amplitude even as peptide dosing continues. The standard research solution is cycling: 8 weeks on, 4 weeks off allows receptor resensitisation. Alternatively, rotating peptide classes (switching from GHRP-2 to ipamorelin) can restore response by engaging slightly different receptor binding profiles. Research from the Journal of Endocrinology found that subjects who cycled CJC-1295/ipamorelin maintained IGF-1 elevations at 12 and 24 weeks, while continuous-use groups showed 40% attenuation by week 16.

Chronic wounds that plateau after 4–6 weeks of standard care often have underlying signaling deficits—downregulated growth factor receptors, persistent biofilm, or impaired perfusion. Peptides like BPC-157 address signaling failures but cannot compensate for untreated infection or ischemia. Combine peptide therapy with debridement and vascular assessment. If the wound remains non-responsive after 8 weeks with peptides, the issue is structural (non-healing bone, foreign body) or systemic (uncontrolled diabetes, autoimmune disease), not peptide-responsive.

Consider Cerebrolysin or Dihexa for neuroprotection and BDNF upregulation. CIRS brain fog often involves cytokine-induced hippocampal damage that doesn't resolve immediately when systemic inflammation drops. The neural tissue needs active repair. Cerebrolysin provides neurotrophic support through multiple growth factors; Dihexa enhances synaptic density and has shown cognitive improvements in animal models of neurodegeneration. Dosing: Cerebrolysin 30ml IV over 10 days, Dihexa 5–10mg oral daily. Neither replaces VIP nasal spray (which addresses MSH and hypothalamic dysfunction), but they target neuroplasticity pathways VIP doesn't directly affect.

Combination use is not well-studied. KPV and BPC-157 operate through pathways independent of TNF-α blockade, suggesting additive effects are theoretically possible without overlapping toxicity. However, no published trials have evaluated peptides combined with infliximab, adalimumab, or vedolizumab. The safety profile of peptides in isolation appears favourable. GI upset and injection site reactions are the primary reported side effects. But immunomodulatory peptides could theoretically interfere with biologic efficacy if they alter T-cell populations in unpredictable ways. If you're on a biologic, introducing peptides without prescriber oversight creates unquantified risk.

Collagen peptides are the only peptide class with long-term safety data spanning 24+ weeks. Doses of 10–15g daily show progressive improvement in joint comfort through week 12, with effects maintaining through week 24. Unlike injectable peptides, oral collagen has no injection site reactions, no reconstitution requirements, and integrates easily into pre- or post-training nutrition. Mix it into post-workout shakes for consistent bioavailability.

Add immune-modulating peptides like Thymalin to address persistent T-regulatory cell suppression. Many CIRS patients clear biotoxins and reduce inflammatory markers (C4a, TGF-beta-1) but remain symptomatic due to immune system retraining failure. The body stays locked in a pro-inflammatory state even after the trigger is removed. Thymalin's mechanism (enhancing thymic output of functional T-regs) directly targets that persistent dysregulation. Typical protocols run 10mg subcutaneous daily for 10–20 days, reassess inflammatory markers, then repeat cycles as needed. The peptide does not replace binders or VIP. It addresses a downstream immune failure that those treatments don't correct.

Peptide effects are dose-dependent and timeline-specific. If you're using standard BPC-157 dosing (250–500 mcg twice daily) and seeing no subjective improvement by day 10–14, verify three things: (1) peptide storage temperature. Was it refrigerated continuously since reconstitution? (2) Injection technique. Are you injecting subcutaneously (into fat layer) rather than intramuscularly? (3) Dosing consistency. Missed doses reduce tissue-level peptide concentrations significantly. Objective markers (reduced swelling, improved range of motion, less pain on movement) may precede subjective awareness. Compare week-two mobility to week-one baseline rather than expecting dramatic day-to-day changes.

Impure peptides either do nothing or produce unpredictable effects. Peptide synthesis requires exact amino acid sequencing. A single substitution changes the molecular structure and eliminates biological activity. We've tested peptides from unverified suppliers and found purity ranging from 60-85%, with some samples containing no active peptide at all. Real Peptides uses small-batch synthesis with third-party verification to guarantee >98% purity. The threshold where pharmacological effects match published research data.

You'll see some fat loss from lipolytic activation, but without the training stimulus to preserve muscle, you'll lose lean mass alongside fat. That's weight loss, not recomposition. GH and IGF-1 elevation can't prevent muscle protein breakdown if there's no mechanical tension signal telling the body to retain that tissue. A 2015 study in the American Journal of Physiology found that GH administration without resistance training produced no net change in lean mass despite elevated IGF-1 levels. Fat loss occurred, but so did muscle loss in a 1:1 ratio.

Administer peptides during the proliferation phase (weeks 1–6 post-injury) for maximum effect. BPC-157 and TB-500 work by accelerating processes already underway. Fibroblast migration, collagen synthesis, angiogenesis. If you're six months past injury and in the remodeling phase, peptides can still improve tissue organization and reduce scar tissue formation, but the largest gains occur when the body is actively rebuilding, not maintaining.